Can dotalizumab (Jemperli) treat rectal cancer?

Dotalizumab (Jemperli) is approved to treat ovarian cancers with highly unstable microsatellite mismatches (dMMR) or deficient DNA mismatch repair (dMMR), but not rectal cancers. The mechanism of action of dotalizumab is mainly to enhance the immune system's attack on cancer cells by inhibiting the signaling pathway on the PD-1 (programmed death 1) receptor. It is a promising treatment option for patients with ovarian cancer.

However, research and clinical trials in the field of immunotherapy have been evolving in recent years, and perhaps beyond the deadline of my knowledge, more studies have been conducted to explore the therapeutic potential of dotalizumab in other cancer types, including rectal cancer. Rectal cancer is typically a microsatellite stable (MSS) tumor, meaning it typically does not have dMMR or MSI-H (microsatellite instability high) characteristics, which are the primary indications for dotalizumab in the treatment of ovarian cancer.

In research and clinical practice, scientists and doctors have been exploring the expansion of indications for different immunotherapy drugs in order to provide new treatment options for patients with more cancer types. Therefore, if you or someone you know has rectal cancer or other cancer types and is interested in dotalizumab or other immunotherapy drugs, it is strongly recommended that you consult a medical professional for the latest treatment recommendations and information.

Dotilizumab is not approved to treat rectal cancer. However, the field of medicine is constantly advancing and treatment options may change in the future, so patients and physicians should stay tuned for the latest research and treatment advances. Final treatment decisions should be made by a medical professional based on the patient's specific circumstances and the latest clinical guidelines.

Dotalizumab is not currently on the market in China, and it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase dotalizumab through overseas channels. There are only original drugs available abroad, mainly from the United States, and the price is as high as about 50,000 yuan.